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The neutralization epitope(s) of the hepatitis E virus (HEV) was studied by an in vitro neutralization assay using antibodies
obtained by immunization of mice with 51 overlapping 30-mer synthetic peptides spanning the region 221–660 amino acids
(aa) of the HEV open reading frame 2 encoded protein (pORF2) and 31 overlapping recombinant proteins of different sizes
derived from the entire pORF2 of the HEV Burma strain. Antibodies against synthetic peptides and short recombinant
proteins of ;100 aa did not neutralize HEV, suggesting the HEV neutralization epitope(s) is conformation-dependent.
However, one recombinant protein of ;400 aa in length comprising the pORF2 sequence at position 274–660 aa as well as
all truncated derivatives of this protein containing region 452–617 aa elicited antibodies, demonstrating HEV neutralizing
activity. These findings establish for the first time that the minimal size fragment, designated pB166, that can efficiently model
the neutralization epitope(s) is 166 aa in length and is located at position 452–617 aa of the HEV pORF2. Additionally,
antibodies against pB166 were found to cross-neutralize three different HEV genotypes, suggesting that a common
neutralization epitope(s) may exist within the different HEV genotypes. Thus, recombinant proteins constructed in this study
may be considered as potential candidates for the development of an HEV subunit vaccine as well as for the development
of highly sensitive and specific diagnostic tests. © 2001 Academic Press
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pINTRODUCTION
The hepatitis E virus (HEV), which is currently unclas-
sified (Berke and Matson, 2000), is transmitted primarily
by the fecal–oral route and causes epidemic and spo-
radic cases of hepatitis. Numerous HEV outbreaks have
occurred in many developing countries, resulting in tens
of thousands of people being infected. The mortality from
acute HEV infection ranges from 0.5–1% for the general
population to as high as 20% for infected pregnant
women. Although only a few cases were diagnosed in
industrialized countries, anti-HEV antibodies have been
found in a significant proportion of blood donors or
healthy individuals (Mast et al., 1997; Thomas et al.,
1997). The reason for this relatively high seroprevalence
is not well understood. One possible explanation for this
observation may be subclinical HEV infections acquired
from zoonotic reservoirs (Meng et al., 1997b).
HEV is a nonenveloped virus, approximately 27–34 nm
in diameter, containing a positive-sense, single-stranded
RNA genome of approximately 7.5 kb in length. The viral
genome contains three partially overlapping open read-
1 To whom reprint requests should be addressed at Division of Viral
epatitis, Mail Stop A-33, National Center for Infectious Diseases,
enters for Disease Control and Prevention, 1600 Clifton Road, Atlanta,
A 30333. Fax: (404) 639-1563. E-mail: yek0@cdc.gov.
203ing frames (ORFs), with ORF1 encoding nonstructural
proteins (pORF1), ORF2 encoding a putative 660-amino-
acid (aa) capsid protein (pORF2), and ORF3 encoding a
small protein (pORF3) of uncertain function (Tam et al.,
1991). Full-length genomes of several HEV strains from
Asia and North America have been sequenced (Tam et
al., 1991; Huang et al., 1992; Erker et al., 1999; Wang et al.,
2000). Phylogenetic analysis based on the full-length
sequences suggests the presence of four distinct geno-
types represented by the Burma strain, Mexico strain,
US-1 strain, and the new Chinese variant T1 (Erker et al.,
1999; Wang et al., 2000). More HEV genotypes and sub-
types have been identified using sequences derived
from small PCR fragments (Schlauder et al., 2000). How-
ever, the antigenic structure of this virus has not been
thoroughly studied, although several antigenic regions of
diagnostic relevance were found within HEV pORF1,
pORF2, and pORF3 by using synthetic peptides of differ-
ent sizes (Kaur et al., 1992; Coursaget et al., 1993;
Khudyakov et al., 1994a, 1994b, 1999) and recombinant
roteins (Yarbough et al., 1991; Li et al., 1994, 1997). The
HEV neutralization epitope(s) has not yet been identified.
One well-established approach to define neutraliza-
tion epitopes is by an analysis of virus mutants resistant
to neutralizing monoclonal antibodies. This approach
was successfully applied to many viruses, for example,
picornaviruses (Diamond et al., 1985). However, it is not
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204 MENG ET AL.applicable to HEV because of the absence of character-
ized HEV mutants, although two neutralizing monoclonal
antibodies were recently prepared by phage display
(Schofield et al., 2000). Another approach is by means of
detecting neutralizing antibodies against numbers of
synthetic peptides and recombinant proteins. Such
large-scale testing can be performed only using an in
vitro neutralization assay. However, the lack of an effi-
cient cell culture system capable of supporting HEV
propagation has hampered the development of such a
traditional assay. Recently, a PCR-based in vitro HEV
neutralization assay was developed (Meng et al., 1997a)
on the basis of our previous observation that the infec-
tion of HEV to a human hepatocarcinoma cell line, PLC/
PRF/5, can be detected by PCR over 3 weeks in vitro
(Meng et al., 1996). Antibodies against the HEV recom-
inant C2 protein comprising the C-terminal two-thirds
225–660 aa) of the HEV Burma pORF2 (Purdy et al., 1992)
ere found to neutralize the HEV Burma, Mexico, and
akistan strains by using the in vitro neutralization assay
Meng et al., 1998). This finding suggested that the HEV
eutralization epitope(s) might be located within the C-
erminal part of its pORF2.
In the present study, 51 overlapping 30-mer synthetic
eptides spanning the entire C2 protein and 31 overlap-
ing recombinant proteins of different sizes derived from
he entire Burma pORF2 were prepared and used to
mmunize mice. All immune sera were tested by the in
vitro neutralization assay. Antibodies obtained against
recombinant proteins containing region 452–617 aa dem-
onstrated specific HEV neutralizing activity. These data
establish for the first time that the minimal size fragment
of the HEV pORF2 that can efficiently model the neutral-
ization epitope(s) is 166 aa in length and is located at
position 452–617 aa. These recombinant proteins that
efficiently model the HEV neutralization epitope(s) may
be considered as candidates for the development of an
HEV subunit vaccine as well as for the development of
highly sensitive and specific diagnostic tests.
RESULTS
Neutralizing activity of antibodies against synthetic
peptides
Fifty-one immune sera against BSA-conjugated HEV
synthetic 30-mer peptides spanning the region at posi-
tion 221–660 aa of the Burma HEV pORF2 (Khudyakov et
al., 1999) were tested by both enzyme immunoassay
(EIA) and the in vitro neutralization assay. All of the
serum samples were immunoreactive to the BSA carrier
protein, suggesting that mice developed immune re-
sponses to these conjugated antigens. However, anti-
bodies immunoreactive with the corresponding synthetic
peptides were identified in only 31 of the 51 (61%) serumsamples. These immunoreactive samples appeared to
cluster into five groups: group 1 (4 peptides derived from
region 221–271 aa), group 2 (6 peptides derived from
region 301–363 aa), group 3 (10 peptides derived from
region 381–471 aa), group 4 (10 peptides derived from
region 483–601 aa), and group 5 (1 peptide derived from
region 631–660 aa). However, when the 51 immune sera
were tested by the in vitro neutralization assay, none of
them demonstrated neutralizing activity to either the HEV
Burma or Mexico strain (data not shown). Since antibody
mixtures have been shown to enhance an antibody’s
neutralizing activity (Martinez and Melero, 1998), antisera
from each group were pooled and retested by the in vitro
neutralization assay. None of the pooled sera demon-
strated any neutralizing activity (data not shown). There-
fore, although antibodies obtained by immunization of
mice with HEV synthetic peptides could be detected by
EIA, none of the antisera, either alone or pooled, neu-
tralized HEV in the in vitro neutralization assay. These
TABLE 1
Recombinant HEV–GST Fusion Proteins and Their Immunoblot
eactivity to an Immune Serum Sample against the HEV Pakistan
train
HEV–GST
fusion protein
Location
(aa)
Length
(aa)
Predicted size
(kDa)
Immunoblot
analysis
pA1 1–103 103 37.3 1
pA2 42–150 109 38.0 1
pA3 72–174 103 37.3 1
pA4 113–236 124 39.6 1
pA5 153–265 113 38.4 2
pA6 189–305 117 38.9 2
pA7 245–356 112 38.3 2
pA8 274–384 111 38.1 2
pA9 336–444 109 38.0 1
pA10 364–475 112 38.3 1
pA11 393–507 115 38.7 1
pA12 421–540 120 39.3 1
pA13 452–580 129 40.2 2
pA14 499–617 119 39.1 2
pA15 541–660 120 39.2 1
pF1 1–417 417 71.9 1
pF2 113–507 395 69.5 1
pF3 189–580 392 69.1 1
pF4 274–660 387 68.6 1
pN309 309–660 352 64.7 1
pN336 336–660 325 61.8 1
pN364 364–660 297 58.7 1
pN393 393–660 268 55.5 1
pN421 421–660 240 52.4 1
pN452 452–660 209 49.0 1
pN499 499–660 162 43.8 1
pC617 274–617 344 63.8 1
pC580 274–580 307 59.8 1
pC540 274–540 267 55.4 1
pC507 274–507 234 51.7 1
pB166 452–617 166 44.3 1observations suggested that the HEV neutralization
epitope(s) is distinctly different from epitopes eliciting
s
e
e
p
S
p
a
b
s
o
5
r
i
e
l
1
s
o
s
(
i
i
N
p
r
r
t
s
t
i
v
H
a
a
p
d
O
p
a
(
a
s
s
b
w
a
o
i
c
w
a
t
w
p
o
s
t
N
p
nd pC
205HEV NEUTRALIZATION EPITOPE(S)EIA-detectable antibodies and indicated that the neutral-
ization epitope(s) could not be modeled with short linear
synthetic peptides.
HEV–GST fusion proteins
Thirty-one overlapping PCR fragments comprising dif-
ferent regions of the HEV Burma ORF2 sequence were
separately amplified and cloned with the prokaryotic
expression vector pGEX-4T-2. The presence of corre-
sponding fragments in each clone was confirmed by
DNA sequencing. After isopropyl-b-D-thiogalactopyrano-
ide (IPTG) induction, hybrid HEV–GST proteins of the
xpected molecular weight (Table 1) were expressed for
ach clone as shown in Fig. 1. The majority of these
roteins were insoluble and produced inclusion bodies.
ome proteins such as pA1, pA2, pA3, pA4, pA11, pA12,
A13, pA14, pA15, pF2, pN309, pN393, pN421, pN452,
nd pB166 could be found in the soluble fraction of
acterial lysates as well. Almost all of these partially
oluble proteins except for pF2 were derived from the N-
r C-terminal part of the HEV pORF2 and were less than
5.5 kDa (except for pF2 and pN309). The antigenic
eactivity of all recombinant proteins was tested by an
mmunoblot assay with serum samples obtained from an
xperimentally infected cynomolgus macaque inocu-
ated with the HEV Pakistan strain SAR-55 (Pillot et al.,
995). None of these proteins immunoreacted with a
erum sample collected before inoculation. However, 25
f 31 (81%) proteins showed immunoreactivity with a
erum sample collected at day 54 following inoculation
Table 1). This observation demonstrated that the major-
ty of the recombinant proteins used in this study were
mmunoreactive.
eutralizing activity of antibodies against proteins
A1–pA15 and pF1–pF4
FIG. 1. HEV–GST fusion proteins expressed in Escherichia coli
;100-aa-long proteins (pA1, pA2, pA3, pA4, pA5, pA6, pA7, pA8, pA9, p
(pF1, pF2, pF3, and pF4); Lanes 20–26, pF4 derivatives by N-terminal
27–30, pF4 derivatives by C-terminal truncation (pC617, pC580, pV540, a
markers (Low range, Bio-Rad, Hercules, CA).Fifteen immune serum samples against ;100-aa-long
ecombinant proteins (pA1–pA15) and four immune se- aum samples against ;400-aa-long recombinant pro-
eins (pF1–pF4) were first tested for anti-GST by EIA. All
erum specimens were immunoreactive against GST,
hus confirming that all of the recombinant proteins elic-
ted antibodies in immunized mice. However, when the in
itro neutralization assay was performed with both the
EV Burma and Mexico strains, the serum samples
gainst each of the ;100-aa-long recombinant proteins
s well as three of the ;400-aa-long proteins such as
F1 (1–417 aa), pF2 (113–507 aa), and pF3 (189–580 aa)
id not show any neutralizing activity (Figs. 2B and 2C).
nly antisera against pF4, comprising the C-terminal
art (274–660 aa) of pORF2, neutralized both the Burma
nd Mexico strains in the in vitro neutralization assay
Fig. 2C).
To further study the neutralizing activity of antibodies
gainst recombinant proteins, three pools of serum
pecimens were prepared. One pool was composed of
erum specimens obtained by immunization with recom-
inant protein pA8–pA15, the second by immunization
ith protein pF2 and pA12–pA15, and the third with pF3
nd pA14–pA15. The in vitro neutralization assay dem-
nstrated that none of the pools was capable of neutral-
zing either the Burma or the Mexico strain, although the
orresponding sequences of these protein combinations
ere equal to or even longer than that of pF4 (274–660
a). These findings suggested that the HEV neutraliza-
ion epitope(s) can be modeled only with the pF4 protein,
hich is 387 aa in length and is located at the C-terminal
art of the pORF2. None of the short ;100-aa fragments,
r the other ;400 aa fragments lacking the C-terminal
equence of the pORF2, or combinations of these pro-
eins could model this epitope(s).
eutralizing activity of antibodies against truncated
F4 proteins
eparated by SDS–polyacrylamide gel electrophoresis. Lanes 1–15,
11, pA12, pA13, pA14, and pA15); Lanes 16–19, ;400-aa-long proteins
ion (pN309, pN336, pN364, pN393, pN421, pN452, and pN499); Lanes
507); Lane 31, pB166; Lane 32, GST; Lane 33, protein molecular weightand s
A10, pA
truncatTo finely map the HEV neutralization epitope(s), an
dditional 12 immune serum samples prepared against
s (pC6
206 MENG ET AL.recombinant proteins obtained by truncating pF4 from
the N- and/or C-termini were tested by EIA and by the in
vitro neutralization assay. Each of the mouse antisera
immunoreacted with GST by EIA, indicating that the im-
munized mice generated antibodies to these truncated
HEV–GST fusion proteins. Interestingly, as shown in Fig.
2D, immune sera against proteins pN309, pN336, pN364,
pN393, pN421, and pN452, which were derived from pF4
by truncating from the N-terminus at positions 309, 336,
364, 393, 421, or 452 aa, respectively, demonstrated HEV
neutralizing activity similar to antibodies against pF4.
However, when immune sera against a protein truncated
at position 499 aa, designated pN499, were tested, neu-
tralizing activity was not observed. This finding sug-
gested that the region at position 452–499 aa plays an
essential role in modeling the HEV neutralization
epitope(s). Additionally, when serum samples from mice
immunized with the other pF4 derivatives, pC617, pC580,
pC540, and pC507, obtained by truncation from the C-
terminus at positions 617, 580, 540, or 507 aa, respec-
tively, were tested by the in vitro neutralization assay,
only anti-pC617 neutralized both HEV strains (Fig. 2E).
This finding demonstrated that the region between 617
and 660 aa of the pORF2 is not involved in modeling the
HEV neutralization epitope(s), whereas the region be-
tween 580 and 617 aa is essential for eliciting the HEV
neutralizing activity.
Finally, when antisera prepared against a 166-aa-long
protein (pB166), which was derived from pF4 by truncat-
ing from the both N- and C-termini at positions 452 and
617 aa, were tested by the in vitro neutralization assay,
neutralizing activity against both Burma and Mexico HEV
FIG. 2. Localization of the neutralizing antigenic epitope(s) of the
recombinant proteins. (A) C2 protein. (B) Fifteen ;100-aa-long proteins
and pA15). (C) Four ;400-aa-long proteins (pF1, pF2, pF3, and pF4). (D)
pN421, pN452, and pN499). (E) Four C-terminally truncated pF4 derivative
(pB166).strains was observed (Fig. 2F). Thus, the smallest region
identified in the present study that can efficiently modelthe HEV neutralization epitope(s) is 166 aa in length and
is located at position 452–617 aa of the HEV pORF2.
Cross-neutralization of different HEV strains
with anti-pB166
As shown above, pB166 is the minimal size protein
capable of modeling the HEV neutralization epitope(s).
Given its small size, pB166 may contain a smaller
array of antigenic epitopes compared to larger pro-
teins. As a result, pB166 may be expected to be less
prone to nonspecific immunoreactivity than larger pro-
teins. Because of this hypothesis, pB166 was studied
in more detail by conducting additional quantitative
assays to compare the neutralizing activity of antibod-
ies against pB166 with HEV strains from Burma, Paki-
stan, Morocco, Mexico, and the United States repre-
senting the different HEV genotypes and subtypes.
Twofold dilutions starting from 1:10 of the immune
serum against pB166 were prepared and mixed with
100 cell culture infectious doses of each HEV strain.
After incubation at 37°C for 1 h, these mixtures were
inoculated onto PLC/PRF/5 cells. Neutralization was
determined by PCR as described under Materials and
Methods. The end-point neutralization titers of anti-
pB166 for the Burma, Mexico, and US-1 strains were
1:640 and that for the Pakistan strain was 1:1280. The
HEV Morocco strain, however, was not reproducibly
neutralized with anti-pB166 diluted beyond 1:20. These
observations demonstrated that antibodies against
pB166 cross-neutralize the different geographic HEV
strains, although with variable efficiency, suggesting
itis E virus by detection of the neutralizing antibodies against HEV
A2, pA3, pA4, pA5, pA6, pA7, pA8, pA9, pA10, pA11, pA12, pA13, pA14,
N-terminally truncated pF4 derivatives (pN309, pN336, pN364, pN393,
17, pC580, pC540, and pC507). (F) N- and C-terminally truncated proteinhepat
(pA1, p
Seventhat a common neutralization epitope(s) may exist
within the different HEV genotypes and subtypes.
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207HEV NEUTRALIZATION EPITOPE(S)DISCUSSION
An in vitro neutralization assay has traditionally been
efined by the absence of virus-induced cytopathic effect
r the reduction of viral plaques in cell culture. However,
any other direct and indirect markers have been used,
uch as a reduction in the number of infected cell foci
isualized by hemadsorption, immunofluorescence, im-
unoenzyme assay, or a reduction in the presentation of
irus-specific antigens detected by hemagglutination or
IA. As a new marker of neutralization, many laborato-
ies utilize the detection of viral DNA or RNA molecules
n inoculated cells by PCR. This has been particularly
mportant for these viruses that remain refractory to
ropagation in cell culture (Haraguchi et al., 1994;
himizu et al., 1994; Meng et al., 1996, 1997a; Zibert et al.,
997; White et al., 1998; Yang et al., 1998). The exact
mechanisms responsible for virus neutralization are not
well understood and may involve blocking of attachment
and entry, prevention of fusion, and uncoating. Neverthe-
less, all the neutralization tests are based on the as-
sumption that neutralizing antibodies block viral replica-
tion, regardless of the stage at which this effect occurs.
Recently, the mechanism of blocking viral attachment
and entry, the first step in viral replication, has been
successfully applied to several rapid PCR-based neutral-
ization assays for the detection of neutralizing antibodies
against hepatitis C virus (Shimizu et al., 1994; Zibert et al.,
1997), human immunodeficiency virus (Yang et al., 1998),
and human T-cell leukemia virus (Haraguchi et al., 1994).
We previously developed a similar neutralization assay
for HEV based on the identical neutralization mechanism
(Meng et al., 1997a). This assay was shown to be highly
specific and sufficiently sensitive to evaluate the neutral-
izing activity in various anti-HEV serum specimens
(Meng et al., 1998). The neutralization results obtained by
the rapid assay were identical to those obtained by an
assay in which the neutralization was determined after
incubation of inoculated cells for 7 days (Meng et al.,
1996, 1997a).
In this paper, this rapid in vitro HEV neutralization
assay was applied to study the HEV neutralization
epitope(s). In accordance with the sequence of the C2
protein (225–660 aa), 51 overlapping 30-mer synthetic
peptides spanning the Burma strain pORF2 at position
221–660 aa were used in an attempt to model the neu-
tralization epitope(s). However, none of these peptides
elicited neutralizing antibodies. Although synthetic pep-
tides derived from other hepatitis viruses such as hepa-
titis A virus (Emini et al., 1985), hepatitis B virus (Neurath
et al., 1986), and hepatitis C virus (Shimizu et al., 1996)
have been shown to elicit neutralizing antibodies, these
synthetic peptides did not efficiently model the neutral-
ization epitopes of these viruses and, as a result, have
not been used in vaccine development. In general, syn-
thetic peptides form only linear epitopes that have lowintrinsic immunogenicity. Thus, they are not efficient im-
munogens for eliciting a neutralizing antibody response
(Yewdell and Bennink, 1997). The failure of modeling the
HEV neutralization epitope(s) with the synthetic peptides
suggests that this epitope(s) is not a linear epitope(s).
Many neutralization epitopes are conformation-depen-
dent discontinuous epitopes formed by residues derived
from different regions of the unfolded polypeptide chain
when the protein folds (Yewdell and Bennink, 1997). In
such cases, the neutralization epitopes can be modeled
only with protein fragments that contain all of the nec-
essary information to direct the correct folding. As shown
in this study, only proteins containing the region 452–617
aa are able to elicit an HEV neutralizing immune re-
sponse. Deletion of 48 aa (452–499 aa) or more from the
N-terminus or 38 aa (617–580 aa) or more from the
C-terminus of the region 452–617 aa led to the inability of
the protein to elicit neutralizing antibodies. Interestingly,
Li et al. (1997) made an observation that the full-length
pORF2 and a protein containing the N-terminal region at
1–110 aa strongly immunoreacted with HEV acute-phase
sera by immunoblot analysis, but were poorly immuno-
reactive with convalescent sera. Conversely, the recom-
binant protein containing the C-terminal region at 394–
660 aa strongly immunoreacted with both acute- and
convalescent-phase sera. Any extension of this protein
toward the N-terminus or any truncation from the N-
terminus of this protein caused a noticeable loss of
immunoreactivity with convalescent-phase sera. Since
immunoblot analysis does not specifically detect the
neutralizing immune response, there is no direct evi-
dence that the same antibodies were detected by Li et al.
(1997) and in the present study. Nevertheless, there is a
striking similarity in the conformational dependence of
antibody binding by different recombinant HEV antigens.
In addition, Schofield et al. (2000) recently performed a
radioimmunoprecipitation study with two HEV neutraliz-
ing monoclonal antibodies and a set of five C-terminally
truncated pORF2 of the HEV Pakistan strain. The mono-
clonal antibodies precipitated the recombinant protein
corresponding to 112–607 aa but did not precipitate
those terminating at or prior to 578 aa. Although they did
not try to determine the N-terminal binding position for
the monoclonal antibodies, the C-terminal position they
determined is very close to that determined in the
present study.
As shown in the present study, all proteins containing
the HEV neutralizing activity detected by the in vitro
neutralization assay were also specifically immunoreac-
tive with serum specimens obtained from a cynomolgus
macaque experimentally infected with the HEV Pakistan
strain. This finding suggests that the immune response
elicited against these proteins after immunization pat-
terns to some extent the immune response caused by
HEV infection. Furthermore, as shown previously (Purdy
et al., 1993) the recombinant C2 antigen (225–660 aa of
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208 MENG ET AL.the HEV Burma ORF2 protein), which contains the pri-
mary structure of all of the neutralizing recombinant
proteins obtained in this study, when used as immuno-
gen protected cynomolgus macaques from infection fol-
lowing HEV challenge. Taking into consideration that
antibodies obtained against this C2 antigen have been
shown to neutralize different HEV strains in the in vitro
assay used in the present work (Meng et al., 1998) and
hat all neutralizing HEV proteins used in this study as
ell as the C2 antigen are derived from the same HEV
urma strain, it can be hypothesized that the HEV neu-
ralizing activity detected by the in vitro neutralization
ssay is cognate to the HEV protective immune response
n the experimental animal models.
This paper describes the immunoreactivity of proteins
horter than the full-size pORF2. Truncating the N-termi-
al 451 aa (1–451 aa) and/or the C-terminal 43 aa (618–
60 aa) from the full-size pORF2 did not affect the func-
ion of the neutralization epitope(s). Conversely, our pre-
ious results demonstrated that a full-length pORF2
xpressed in a baculovirus system was less efficient in
liciting neutralizing antibodies than the truncated form,
uch as the C2 protein (Meng et al., 1998). Additionally,
s was recently shown, nonhuman primates immunized
ith a full-length recombinant pORF2 expressed in Esch-
richia coli were not protected against challenge with
EV, despite the fact that these animals elicited high
iters of immunoblot-detectable antibodies (Panda et al.,
997). Collectively, these observations suggest that the
EV neutralization epitope(s) may be modeled with vari-
ble efficiency by pORF2 recombinant proteins of differ-
nt sizes and that the presence of the N-terminal domain
ight have an adverse effect on modeling this epitope(s)
y these proteins.
Recently, several research groups reported that the
EV ORF2 protein formed virus-like particles (VLPs)
hen expressed in insect cells (Tsarev et al., 1997;
hang et al., 1997; Li et al., 2000b). Since virions are the
target for neutralizing antibodies it seems logical to as-
sume that VLPs, which model virion macrostructure,
would also efficiently model the neutralizing epitope(s)
and, therefore, efficiently elicit neutralizing antibodies. In
fact, several groups have published experimental evi-
dence that HEV VLPs are very potent immunogens af-
fording protection against both homologous and heter-
ologous challenge in nonhuman primates (Tsarev et al.,
1994, 1997). The strategy presented in this study and
noted by other researchers (Purdy et al., 1993; Li et al.,
2000a; Im et al., 2001) allows for the efficient modeling of
the HEV neutralizing antigenic epitope(s) without the
requirement for modeling the macrostructure into VLP.
Immunization with the recombinant proteins described in
this paper induced synthesis of antibodies with anti-HEV
neutralizing activity detected by the in vitro neutralization
assay. Similar proteins have been used to successfully
protect nonhuman primates against HEV infection (Purdyet al., 1993; Im et al., 2001). These observations strongly
suggest that this alternative strategy should be consid-
ered for the development of promising HEV vaccine can-
didates.
The HEV genome is rather heterogeneous. Therefore,
the virus can be classified into several genotypes and
subtypes (Schlauder et al., 2000; Wang et al., 2000).
However, the effect of sequence heterogeneity on the
HEV antigenic properties, especially on the neutraliza-
tion epitope(s), has not been thoroughly investigated. It
was reported that baculovirus expressed recombinant
proteins containing the pORF2 region of 112–660 aa from
the HEV Pakistan strain (genotype 1, subtype 1b) or the
Burma strain (genotype 1, subtype 1a) induced protective
immune responses to a heterologous Mexico strain (ge-
notype 2) challenge in nonhuman primates (Tsarev et al.,
1997; Yarbough et al., 1997). Also, antibodies against the
C2 protein, which contains the Burma pORF2 fragment of
225–660 aa, efficiently neutralized the HEV Burma, Paki-
stan, and Mexico strains, but not the Morocco strain
(genotype 1, subtype 1c) in the in vitro neutralization
assay (Meng et al., 1998). In the present study, this
observation was confirmed by a quantitative cross-neu-
tralization assay using the immune sera against the
small protein, pB166. This sample neutralized the Burma,
Pakistan, Mexico, and US-1 strains at the end-point titers
of 1:640 to 1:1280, whereas the Morocco strain was
neutralized at a lower titer of 1:20. This is the first exper-
imental evidence that the HEV US-1 strain (genotype 3)
can be cross-neutralized with antibodies against the
HEV Burma strain. The reason for the lower efficiency of
neutralization of the HEV Morocco strain noted previ-
ously (Meng et al., 1999) and confirmed in the present
study is not clear. One probable explanation is that
because the Morocco strain was obtained from a pool of
fecal specimens collected from 15 HEV-infected individ-
uals from an outbreak of hepatitis E in Morocco, it is
possible that this pool contains one or more neutraliza-
tion escape mutants.
In conclusion, this study has shown that the region
at position 452–617 aa of pORF2 is the minimal size
fragment capable of efficiently modeling the HEV neu-
tralization epitope(s). Antibodies obtained by immuni-
zation of mice with pB166, a 166-aa-long recombinant
protein corresponding to the identified region, can
cross-neutralize several different geographic HEV
strains in the in vitro neutralization assay. We believe
the data presented in this paper should be taken into
account in the development of HEV vaccines. In addi-
tion, we believe that further characterization of the
HEV neutralization epitope(s) will be very helpful in
identifying HEV neutralization escape mutants, as has
been shown with the “a” determinant of the hepatitis B
virus (Seddigh-Tonekaboni et al., 2000).
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Cell culture
PLC/PRF/5 was grown in Dulbecco’s modified Eagle’s
medium (Gibco BRL, Grand Island, NY) supplemented
with 10% heat-inactivated fetal bovine serum (HyClone,
Laboratory, Int., Logan, UT) and incubated at 37°C with
5% CO2. For the in vitro neutralization assay, trypsinized
cells were seeded into 24-well, flat-bottom culture plates
at a concentration of 105 cells per well and incubated to
orm cell monolayers.
irus stocks
Inocula containing the HEV Burma, Pakistan, Morocco,
nd Mexico strains were previously described (Meng et
l., 1998). The HEV US-1 strain was obtained from a fecal
ample collected from a 62-year-old white male with
cute hepatitis without a history of recent travel outside
he United States (Kwo et al., 1997). This inoculum was
indly provided by K. McCaustland [Hepatitis Branch,
enters for Disease Control and Prevention (CDC), At-
anta, GA] and prepared as previously described (Meng
t al., 1998).
ynthetic peptides
Fifty-one overlapping 30-mer peptides spanning the
2 protein sequence were previously described
Khudyakov et al., 1999).
Construction of HEV recombinant plasmids
Thirty-one HEV recombinant plasmids were con-
structed by cloning PCR fragments with pGEX-4T-2 vec-
tor (Pharmacia Biotech Inc., Piscataway, NJ). All PCR
fragments were amplified from a recombinant plasmid
containing the whole HEV Burma strain ORF2 sequence
(kindly provided by Dr. S. Kamili, Hepatitis Branch, CDC).
Primers used for PCR amplification were selected based
on the Burma strain sequence (Tam et al., 1991) and
modified to contain a BamHI or XhoI restriction site to
facilitate cloning (not shown). PCR was performed using
the Expand High Fidelity PCR System (Boehringer Mann-
heim, GmbH, Mannheim, Germany). PCR products were
purified with the QIAquick PCR Purification Kit (Qiagen
Inc., Valencia, CA). Both purified PCR products and
pGEX-4T-2 vector were digested with BamHI and XhoI
Boehringer Mannheim) at 37°C overnight, ligated using
4 DNA ligase (Pharmacia Biotech) at 16°C overnight,
nd then used to transform E. coli competent JM109 cells
Promega, Madison, WI). Recombinant plasmids were
ecovered from transformants by using the Wizard Mini-
rep DNA Purification system (Promega). The presence
f insert was confirmed by PCR using two primers with
he sequences, 59-CAG GGC TGG CAA GCC AC and
9-CGT CAT CAC CGA AAC GC, derived from regions
lanking the multiple cloning site of pGEX-4T-2. The pri-ary structure of the inserts was finally confirmed by
NA sequencing with a Model 373 or 377 automated
NA sequencer (ABI, Foster City, CA).
xpression of HEV–GST fusion proteins
E. coli JM109 cells transformed with the recombinant
lasmids were grown at 37°C overnight in Luria broth
LB) medium containing 50 mg/ml ampicillin. The over-
night culture was diluted 20 times with fresh LB medium
containing the same concentration of ampicillin and
grown at 37°C for 3 to 4 h until an optical density value
of 0.6–1.0 at 600 nm was reached. The gene expression
was induced by adding IPTG (Sigma Chemical Co., St.
Louis, MO) into the culture to a final concentration of 1
mM. After 4 h of incubation at 37°C with constant shak-
ing, the cells were pelleted by centrifugation at 6000 g for
15 min at 4°C and then resuspended with 3 ml of lysis
buffer (50 mM Tris, pH 8.0, 1 mM EDTA, 100 mM NaCl) for
each gram of packed cells. The suspension was incu-
bated on ice for 30 min with a final concentration of 0.2
mM phenylmethylsulfonyl fluoride (Sigma) and 0.5 mg/ml
of lysozyme (Sigma). Then, 4 mg of deoxycholic acid was
added per gram of E. coli cells while stirring continuously
at room temperature for 5 min. The lysate was incubated
with 20 U/ml of DNase (Boehringer Mannheim) at room
temperature until it was no longer viscous and centri-
fuged at 10,000 g for 20 min at 4°C. The supernatant was
transferred to a fresh tube and purified with Bulk and
Redipack GST Purification Modules (Pharmacia Biotech).
The pellet containing insoluble HEV–GST fusion protein
was washed completely, resuspended and homogenized
with phosphate-buffered saline (PBS), and stored in ali-
quots at 270°C.
Immunoblot analysis of HEV recombinant proteins
Aliquots of each homogenized HEV–GST fusion pro-
tein were separated by electrophoresis on precast 12%
sodium dodecyl sulfate (SDS)–polyacrylamide gels (Bio-
Rad, Richmond, CA) followed by blotting onto nitrocellu-
lose membranes (Bio-Rad). The nitrocellulose mem-
branes were incubated overnight with blocking buffer
containing 10% normal goat serum, 1% bovine serum
albumin (BSA), and 0.05% Tween 20 in 0.01 M PBS and
then incubated for 1 h with serum samples collected
from a cynomolgus macaque experimentally infected
with the HEV Pakistan strain (Pillot et al., 1995) diluted
1:100 in blocking buffer. The membranes were rinsed
three times with wash buffer (PBS with 0.05% Tween 20)
and incubated for 1 h with affinity-purified goat anti-
human immunoglobulin G (IgG, Pierce) conjugated with
horseradish peroxidase diluted 1:6000 in blocking buffer.
After three washes, color development was carried out
with 3,39-diaminobenzidine as substrate (Bio-Rad).
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All synthetic peptides were conjugated with BSA by
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydro-
chloride coupling methods using a commercially avail-
able kit (Pierce, Rockford, IL). Each of the BSA-conju-
gated peptides and the HEV–GST fusion proteins was
emulsified with adjuvant (TiterMax; CytRx, Atlanta, GA)
and used to immunize a group of three or four female
Hsd NIHS mice that were 6–9 weeks old. Mice were
inoculated subcutaneously at two sites on the back with
a total of 100 ml of the emulsion containing 50 mg of the
onjugated peptide or the fusion protein. Four weeks
ater, the mice were boosted with an intraperitoneal
njection of 10 mg of the same peptide or protein diluted
in 100 ml of PBS. Seven days later, the mice were bled
rom the heart. The immune sera obtained from each
roup of mice were pooled together and inactivated by
eating at 60°C for 30 min. Aliquots were prepared and
tored at 270°C. Immune sera against BSA and GST
ere prepared using the same procedure.
nzyme immunoassay
The protocol used for detecting antibodies against
EV synthetic peptides was previously described
Khudyakov et al., 1999).
In vitro PCR-based neutralization assay
This assay has been previously described (Meng et
al., 1997a, 1998). Briefly, approximately 100 cell culture
infectious doses of an HEV inoculum diluted in 100 ml of
anks’ solution were mixed with 100 ml of immune sera
at a dilution of 1:10. After incubation at 37°C for 1 h, the
mixture was inoculated onto a cell monolayer of PLC/
PRF/5. After adsorption for 2 h at 37°C, the cells were
washed three times with Hanks’ solution followed by
immediate RNA extraction with TRIzol reagent (Gibco
BRL) according to the manufacturer’s instructions fol-
lowed by reverse transcription and nested PCR using a
set of universal HEV PCR primers. The external primers
were JM-2 (59-CCG ACA GAA TTG ATT TCG TCG GC) and
JM-5 (59-CCG TAA GTG GAC TGG TCG TAC TC). The
internal primers were JM-3 (59-GTT GTC TCG GCC AAT
GGC GAG CC) and JM-4 (59-TCG GCG GCG GTG AGA
GAG AGC CA). Both the first-round and the second-round
amplifications were carried out according to the follow-
ing cycling program: denaturation at 94°C for 45 s, an-
nealing at 60°C for 20 s, extension at 72°C for 60 s, for
30 cycles. Amplicons were separated by agarose gel
electrophoresis with size markers and visualized by
ethidium bromide fluorescence. Neutralization was de-
termined by the absence of detectable HEV RNA in the
inoculated cell culture. A normal mouse serum control,
anti-BSA or anti-GST serum control, virus control, and
uninoculated cell control were processed for detection of
HEV RNA at the same time.ACKNOWLEDGMENTS
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